Company Overview and News

 
SGX sees share buyback boom: Why and what does it mean for investors?

2018-09-12 channelnewsasia
SINGAPORE: Singapore-listed companies have been repurchasing more of their own shares this year, with stock buybacks hitting a near three-year high last month, and analysts think this trend could continue for the rest of 2018 amid a volatile market.
SPXCY UOVEF SPXCF C09 UOVEY CDEVF CDEVY U11 O39 S68

 
CapitaLand gets a 'buy' on active capital recycling and portfolio rebalancing

2018-08-23 theedgemarkets
SINGAPORE (Aug 23): CapitaLand’s recent acquisitions in Singapore and China show continued efforts to recycle capital and rebalance its portfolio mix, say analysts.
C09 CDEVF CDEVY

 
No catalysts in sight for CityDev as new housing initiatives threaten to curb buying sentiment: Jefferies

2018-08-21 theedgemarkets
SINGAPORE (Aug 21): Jefferies is reiterating its “hold” call on City Developments (CDL) with a price target of S$11, which is based on a 22% discount to a RNAV of S$14, with the view that there are no immediate catalysts for the stock.
C09 CDEVF CDEVY

 
CapitaLand-CDL JV secures prime site in Sengkang Central for S$777.8 mil

2018-08-16 theedgemarkets
SINGAPORE (Aug 16): CapitaLand and City Developments Limited (CDL) jointly announced that they, via a joint venture (JV), have secured a mixed-use residential and commercial site in Sengkang Central for S$777.78 million.
C09 CDEVF CDEVY

 
Singapore home sales soar in July on minute-to-midnight buying

2018-08-15 theedgemarkets
SINGAPORE (Aug 15): Private home sales in Singapore soared to the highest in 16 months in July as buyers rushed to snap up properties hours before curbs aimed at quelling speculation came into effect.
C09 CDEVF CDEVY

 
Singapore home sales soar in July on minute-to-midnight buying

2018-08-15 malaymail
SINGAPORE, Aug 15 — Private home sales in Singapore soared to the highest in 16 months in July as buyers rushed to snap up properties hours before curbs aimed at quelling speculation came into effect.
C09 CDEVF CDEVY

 
CityDev posts 79.5% rise in 2Q earnings to S$205m; expects residential sales to moderate

2018-08-10 theedgemarkets
SINGAPORE (Aug 10): City Developments (CDL) announced earnings of S$204.8 million for the 2Q ended June, up 79.5% from its 2Q17 earnings of S$114.1 million a year ago, backed by stronger sales recognition during the period under review.
C09 CDEVF CDEVY

 
Singapore curbs may make property a buy, says CapitaLand CEO

2018-08-08 theedgemarkets
SINGAPORE (Aug 8): Singapore’s latest round of property curbs are probably enough to cool the market, and may present buying opportunities, the head of the city-state’s biggest developer said.
C09 CDEVF CDEVY

 
CDL posts 79.5% rise in Q2 profit on the back of strong sales - Channel NewsAsia

2018-08-08 channelnewsasia
SINGAPORE: City Developments Limited’s (CDL) second-quarter net profit soared 79.5 per cent from a year ago, on the back of strong sales.
C09 CDEVF CDEVY

 
Singapore developers attack cooling measures, Straits Times says

2018-07-07 malaymail
SINGAPORE, July 7 — A leading developers’ group in Singapore has challenged the government’s latest round of property-cooling measures, saying that there’s no rationale for the steps as the market is only in the early stages of a recovery, the Straits Times reported, citing a statement from the group.
U14 C09 UOLGF CDEVF UOLGY CDEVY

 
Curb on enthusiasm: Singapore property measures hit developers, investors

2018-07-06 theedgemarkets
SINGAPORE (July 6): Singapore's surprise move to intensify property curbs marks the strongest cooling measures in the island nation in five years, putting a damper on a nascent resurgence in the housing market and posing risks to developers' margins.
5UX C09 CDEVF CDEVY

5
Singapore announces surprise property curbs to cool market

2018-07-06 malaymail
SINGAPORE, July 6 — Singapore’s renewed clampdown on speculative property demand sent real estate stocks reeling today, as analysts predicted the end of a nascent home price rebound and the deflation of a buoyant market for collective sales.
5UX CDEVY WTHEF D05 C09 DBSDF UOLGF UOVEF DBSDY U14 C UOLGY O39 U11 CGBBW UOVEY CDEVF KPPLF

 
Fall ahead of U.S. tariffs; Singapore sinks to 14-month low

2018-07-06 theedgemarkets
(July 6): Southeast Asian stock markets fell on Friday, as investors closed positions and waited anxiously for the impending tariffs on Chinese imports by U.S. President Donald Trump, with Singapore falling more than 2% to a 14-month low.
U14 C09 UOLGF CDEVF UOLGY CDEVY

1
Singapore's Decisive Property Crackdown Set to Damp `Euphoria'

2018-07-06 theedgemarkets - 1
(July 6): Singapore’s surprise crackdown to drive out speculative investments from the property market will probably hit collective sales that had become popular with developers of late, sending stocks reeling.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

 
Singapore’s decisive property crackdown set to damp ‘euphoria’

2018-07-06 thestar.com.my
SINGAPORE: Singapore’s surprise crackdown to drive out speculative investments from the property market will probably hit collective sales that had become popular with developers of late, sending stocks reeling. The tightened rules, rolled out a day after the central bank noted “euphoria” in the property market, sharply increase buyers’ stamp duties for entities such as developers. Singapore’s benchmark Straits Times Index dropped as much as 2.
UOVEF 5UX DBSDY U14 5H0 UOLGY CDEVY U11 O39 WTHEF D05 C09 DBSDF UOLGF UOVEY CDEVF KPPLF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...